Scandinavian ChemoTech

VQ Animal Care Inc, our US subsidiary, has received an order of approximately MSEK 1,3 from MedVet, the leading veterinarian owned and led family of specialty and emergency hospitals and urgent cares known for delivering high quality, compassionate care to more than 500,000 patients each year in communities throughout the United States. This order marks a major milestone in the US by ChemoTech's animal care division, Vetiqure, as the awarding of the supplier contract follows a comprehensive evaluation.

"After great clinical success through our Animal Care operation over the last 12 months, and following significant orders in the US and Sweden, we can see the acceptance and value that the TSE innovation can bring to veterinary cancer care. It is a very exciting time to be the co-innovator of a therapy that has started to transform from a vision and opportunistic targets into the paradigm change we now are witnessing." - says Mohan Frick, CEO, and cofounder of Scandinavian ChemoTech.

Brendan Boostrom, DVM, MS, Diplomate, ACVIM (Oncology), who is a Board-Certified Veterinary Oncologist at MedVet Northern Virginia adds, "We are excited to offer these new TSEtreatments (Tumour Specific Electroporation) that provide greater access to advanced cancer care for pets and their families. With TSE (Tumour Specific Electroporation) we can effectively treat tumors and scars with minimal side effects. Additionally, these patients are often sedated rather than anesthetized, which improves safety and affordability. This treatment also aligns well with my personal goal for pets- to provide more good days with their families."

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.